Tru Niagen (ChromaDex)
Most clinically validated NAD+ precursor with 35+ published studies, 3x FDA GRAS status, and the only patented NR ingredient; positions as the pharmaceutical-grade option in a supplement market
NOT CLEARED
No FDA clearance, registration, or CE marking found.
Key facts at a glance.
- Founded
- 1999
- Headquarters
- Los Angeles, CA, USA
- Price range
- $1.43–$1.43
- Trustpilot
- 4.2 / 5 (14)
The real price over three years.
Total cost of ownership · 3yr
| Hardwareone-time | $1.43 |
| 3-year total | $1.43 |
What the device does.
- + Patented Niagen (nicotinamide riboside / NR) ingredient
- + Clinically proven to increase NAD+ by 40-50% in 2 weeks
- + 3x FDA GRAS determination and NDI status
- + NSF Certified for Sport on select products
- + Available in 150mg, 300mg, and Pro 1000mg doses
- + Stick pack format for on-the-go use
- + Beauty and Immune specialty SKUs
- + Backed by 35+ published human clinical studies on NR
The trade-offs.
- + Patented Niagen (nicotinamide riboside) ingredient with the strongest published evidence base in the NAD+ category
- + 35+ human clinical studies — clinical-grade evidence depth no NMN brand matches
- + 3× FDA GRAS determinations and NDI (New Dietary Ingredient) status
- + NSF Certified for Sport on select SKUs (rare in the NAD+ space)
- + Multiple dose options (150 mg, 300 mg, Pro 1000 mg) and formats (capsules, stick packs)
- − Premium pricing — $45/mo subscription at the standard 300 mg dose
- − Lower per-capsule dose than NMN competitors (300 mg NR vs 500–1000 mg NMN per cap)
- − Some users report cancellation friction on the subscription program
- − Effects are biomarker-driven (NAD+ elevation) — many users won't subjectively notice
- − NR-vs-NMN debate creates persistent buyer confusion that brand marketing can't fully resolve
Mainstream health-conscious consumers 35+, people seeking clinically-proven NAD+ supplementation, athletes
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
Tru Niagen is the consumer brand of ChromaDex’s patented Niagen ingredient — a stabilized form of nicotinamide riboside (NR), one of the two NAD+ precursors the consumer market is built around (the other being NMN). It has the strongest published evidence base in the entire longevity-supplement category: 35+ human clinical studies, three separate FDA GRAS determinations, NDI status, and NSF Certified for Sport on select SKUs.
In the 2026 NAD+ market — where most competitors sell unpatented NMN or commodity NR with thin published validation — Tru Niagen’s structural advantage is regulatory and evidentiary, not just marketing. That matters more in 2026 than it did before, because FDA’s 2022 NDI rejection of NMN has left NMN in a contested supplement-vs-drug status that NR doesn’t share.
What We Measured
Note: This review is based on ChromaDex’s published clinical trial portfolio (PubMed-indexed), the FDA GRAS determinations, and consumer pricing data. Hands-on supplement-quality testing (third-party COA verification) is pending. We will commission a third-party assay of Tru Niagen capsules to confirm Niagen content matches label claim.
Published clinical evidence
ChromaDex has funded and published 35+ human RCTs on Niagen. The most-cited studies show NR raises NAD+ by 40–50% in healthy adults within 2 weeks at 300 mg/day. Studies have measured effects on inflammation markers, mitochondrial function, blood pressure, and cardiovascular markers. Sample sizes vary; some are manufacturer-funded (always disclose); the aggregate evidence is the strongest in the consumer NAD+ category.
Comparison to NMN published evidence
Published NMN human trials exist (a handful at 250–500 mg dose ranges showing NAD+ elevation comparable to NR), but the volume is dramatically smaller — roughly 5–8 published human RCTs vs 35+ for NR. NMN may eventually catch up; today, NR has the depth.
Regulatory profile
Niagen has 3× FDA GRAS determinations (the “Generally Recognized as Safe” pathway) and NDI status. This means FDA has reviewed safety data and accepted the ingredient as a dietary supplement on multiple occasions. NMN, by contrast, was rejected as an NDI by FDA in 2022 — FDA classified it as an investigational drug rather than a supplement. Many NMN brands continue selling under enforcement discretion, but the legal status is contested.
NSF Certified for Sport
Tru Niagen Pro 1000 mg holds NSF Certified for Sport — a third-party certification that the supplement is free of banned substances and matches label claim. Athletes subject to drug testing should view this as a structural advantage; very few longevity supplements carry NSF Sport.
3-Year Cost of Ownership
| Component | Cost |
|---|---|
| Tru Niagen 300 mg subscription (~$45/mo × 36) | ~$1,620 |
| Tru Niagen Pro 1000 mg subscription (~$80/mo × 36) | ~$2,880 |
| Tru Niagen 150 mg subscription (~$30/mo × 36) | ~$1,080 |
| 3-year total — 300 mg standard dose | ~$1,620 |
Compare: ProHealth Longevity NMN ($60–80/mo, ~$2,200/3yr), DoNotAge NMN powder ($30/mo, ~$1,100/3yr), Wonderfeel Youngr NMN ($85/mo, ~$3,060/3yr).
Tru Niagen at the 300 mg dose lands mid-pack on cost — but ahead on evidence depth and regulatory profile.
Regulatory Status
Not FDA-Cleared (as a drug). Tru Niagen is a dietary supplement under DSHEA. The Niagen ingredient itself has 3× FDA GRAS determinations and NDI status — meaning FDA has reviewed safety data and the ingredient is on file as a supplement, not as an investigational drug.
This is the central editorial distinction from NMN supplements. NR (Niagen) is a stable, FDA-acknowledged supplement. NMN is currently in a contested status — FDA has signaled it should be regulated as a drug, but enforcement is discretionary, and many brands continue selling. For a buyer who wants regulatory certainty about what they’re putting into their body, NR has the cleaner status.
What the Evidence Doesn’t Tell You
NR raises NAD+ by 40–50% — that’s measured. What that NAD+ elevation does for you — energy, recovery, longevity, cognition — is much harder to characterize. Most NR studies measure surrogate biomarkers (NAD+ levels, inflammation markers, mitochondrial function); they don’t measure subjective wellbeing or longevity outcomes (those would require decade-plus trials).
This is the right context for setting expectations: Tru Niagen will reliably raise your NAD+. Whether you’ll feel anything is highly individual, often subtle, and not the primary efficacy claim. Buyers expecting energy-drink-style noticeable effects will be disappointed; buyers running biomarker-tracked longevity protocols will get clean signal.
Verdict: Recommended
Tru Niagen earns the recommendation on the strength of its published clinical evidence (35+ human RCTs), regulatory profile (3× FDA GRAS, NDI, NSF Certified for Sport), and patented Niagen ingredient stability. In a category where most products sell unpatented NMN with thin published validation and contested regulatory status, Tru Niagen is the methodologically defensible answer.
The recommendation is conditional on understanding what you’re buying: NAD+ elevation is the measured effect, not subjective transformation. If you’ll track biomarkers (NAD+ levels via TruDiagnostic NAD+ test, inflammation markers via Function Health, biological age via TruAge), Tru Niagen is the cleanest precursor to test against.
If you specifically want NMN despite the regulatory ambiguity, ProHealth Longevity and Wonderfeel Youngr are the strongest options. For NR with the deepest evidence base, Tru Niagen is the standard.
Changelog
- 2026-05-05: Initial review published based on ChromaDex’s published clinical trial portfolio and FDA GRAS / NDI documentation. Third-party COA verification pending.